Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues

Abstract

We have recently reported that a series of ( E)-8-styrylcaffeines and ( E)-2-styrylbenzimidazoles are moderate to very potent competitive inhibitors of monoamine oxidase B (MAO-B). The most potent member of the series was found to be ( E)-8-(3-chlorostyryl)caffeine (CSC) with an enzyme-inhibitor dissociation constant ( K i value) of 128 nM. In the present study, we have prepared additional caffeine and benzimidazole analogues in an attempt to identify compounds with improved MAO-B inhibition potency while still acting reversibly. The most potent inhibitor among the caffeine analogues was ( E)-8-(3,4-dichlorostyryl)caffeine with a K i value of 36 nM, approximately 3.5 times more potent than CSC. The most potent inhibitor among the benzimidazole analogues was ( E)-2-(4-trifluoromethylstyryl)-1-methylbenzimidazole with a K i value of 430 nM. An SAR analysis indicated that the potency of MAO-B inhibition by ( E)-2-styryl-1-methylbenzimidazole analogues depended upon the Taft steric parameter ( E s) of the substituents attached to C-4 of the styryl phenyl ring. Substituents with a large degree of steric hindrance appear to enhance inhibition potency. The proposal that potent MAO-B inhibition by ( E)-8-styrylcaffeines and ( E)-2-styrylbenzimidazoles can be explained by a mode of binding that involves traversing both the entrance and substrate cavities was supported by the finding that 1-methylbenzimidazole only weakly inhibited MAO-B with a K i value of 2084 μM. Without the styryl side chain, 1-methylbenzimidazole is not expected to be able to bind simultaneously to both the entrance and substrate cavities.